Badar M. Mian, MD

Mian is professor of surgery in the division of urology at Albany Medical College in New York.


RP appears more effective against high-risk prostate cancer

April 28, 2022

"It’s very possible that the PSA screening-detected high-risk prostate cancer portends a more favorable outlook when compared with the pre-PSA era, regardless of the type of primary therapy utilized," writes Badar M. Mian, MD.

Findings support safety, feasibility of partial-gland treatment

March 21, 2022

"If adequate cancer control can be achieved by focal or partial-gland treatment, then the favorable adverse event profile could make this a preferred option for a number of men with localized intermediate-risk (and possibly selected high-risk) prostate cancer," writes Badar M. Mian, MD.

Unexpected increase in PSA testing after USPSTF recommendations

January 21, 2022

"It is worth remembering that injudicious use of PSA test, and the downstream consequences of overtreatment and complications, can obscure the benefits associated with PSA-based early detection of prostate cancer," writes Badar M. Mian, MD.